Compare Immunovant Inc. Common Stock (IMVT) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Okta, Inc. — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Okta, Inc. trades at $222.45 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 6.2× Immunovant Inc. Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Okta, Inc. for 44 Days on average.
| IMVT | OKTA | |
|---|---|---|
Market Cap | $6.25B | $38.50B |
Volume | 1,755,411 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $44.96 | $220.21 |
52-Week Low | $17.03 | $62.93 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $5.35B | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKTA trades at $218.00, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $2.61 billion in 2025 with a net income turnaround to $28 million. Recent earnings beats and positive analyst sentiment (73.58% buy ratings) highlight momentum, though high valuation ratios like a P/E of 131.33 pose concerns. Key developments include AI security initiatives unveiled at Oktane 2026, driving media attention.
Outlook: OKTA's focus on AI agent security and identity management positions it for growth in cybersecurity, but elevated valuations and insider selling require caution. Risks include competitive pressures and execution challenges. The consensus price target of $201.30 suggests modest downside, yet innovation catalysts offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
